Welcome to our dedicated page for Autonomix Medical SEC filings (Ticker: AMIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autonomix Medical, Inc. filings document a development-stage medical device company focused on precision nerve-targeted technology and transvascular approaches to peripheral nerve sensing and treatment. Securities registration statements describe the company’s common stock, warrant instruments, offering mechanics, emerging growth company status, smaller reporting company status, financial statements, convertible note proceeds, and related-party transaction disclosures.
Autonomix’s 8-K filings cover material events including Regulation FD clinical-data disclosures, private placement financing agreements involving pre-funded warrants and Series C warrants, annual meeting voting results, board and auditor matters, reverse stock split authority, and Nasdaq continued-listing compliance notices. These records also reflect capital-structure changes and governance actions tied to the company’s public-company status.
Autonomix Medical, Inc. (AMIX) has established an at-the-market equity program under which it may sell shares of common stock with an aggregate offering price of up to $10.525 million from time to time through Ladenburg Thalmann as sales agent or principal. Ladenburg will receive a 3.0% cash commission on gross proceeds and may also conduct privately negotiated transactions, with no minimum sale amount and no escrow arrangement. Based on a September 8, 2026 closing price of $4.58 and 1,959,938 shares outstanding, the company illustrates that issuing 2,298,035 shares would increase shares outstanding to 4,257,973, subject to the 500,000,000 authorized share limit and one‑third public float constraints under Form S‑3 Instruction I.B.6. Autonomix intends to use any net proceeds for working capital and general corporate purposes. The company is a development‑stage medical device business with no product sales revenue, an auditor’s going‑concern explanatory paragraph, and significant risks including potential Nasdaq delisting if a new $5 million Market Value of Listed Securities rule ultimately takes effect and is not satisfied, as well as dilution and price volatility from this ATM program.
Autonomix Medical, Inc. (symbol: AMIX) is the issuer of record for a Form 4 filing submitted to the SEC. KLEMP WALTER V reported acquisition or exercise transactions in this Form 4 filing.
Autonomix Medical, Inc. (AMIX) reported that director Walter V. Klemp received a grant of 13,000 shares of Common Stock as a restricted stock award on September 3, 2026. Following this equity award, he holds 20,118 shares directly, with the award vesting one year from September 3, 2026.
Autonomix Medical, Inc. (symbol: AMIX) is the issuer of record for a Form 4 filing submitted to the SEC. Bisson Lori reported acquisition or exercise transactions in this Form 4 filing.
Autonomix Medical, Inc. (AMIX) reported that director Lori Bisson received a grant of 13,000 shares of common stock on September 3, 2026 as a restricted stock award, bringing her direct holdings to 13,119 shares.
The award is scheduled to vest one year from the issuance date, on September 3, 2027. No transactions are reported under a Rule 10b5-1 trading plan.
Autonomix Medical, Inc. (symbol: AMIX) is the issuer of record for a Form 4 filing submitted to the SEC. Hauser Bradley reported acquisition or exercise transactions in this Form 4 filing.
Autonomix Medical, Inc. (AMIX) reported that CEO and President Bradley Hauser received an equity grant of 27,000 shares of Common Stock on September 3, 2026. The award is described as a restricted stock award vesting one year from the date of issuance of September 3, 2026, and is held as direct ownership. No Rule 10b5-1 trading plan is reported for this grant.
Autonomix Medical, Inc. (AMIX) is calling an annual stockholder meeting for October 29, 2026 to elect five directors, ratify Forvis Mazars, LLP as auditor, and vote on two key capital-structure items. Stockholders are asked to authorize the Board to implement a reverse stock split of outstanding common shares at a ratio between 1-for-2 and 1-for-25, at any time up to one year after the meeting, and to approve an amended and restated 2023 Equity Incentive Plan that would increase shares available for equity compensation. Stockholders of record on September 8, 2026, when 1,828,505 shares of common stock were outstanding, are entitled to one vote per share.
Autonomix Medical, Inc. (AMIX) is registering up to 1,071,826 shares of common stock for resale by a single selling stockholder, issuable upon exercise of Series E common stock purchase warrants at an exercise price of $6.25 per share.
Autonomix will not sell any shares in this offering and will receive cash only if the warrants are exercised, which, if fully exercised for cash, would generate up to about $6.7 million in gross proceeds, planned for working capital. As of August 31, 2026, 1,828,505 shares of common stock were outstanding. The company highlights that issuance of the warrant shares could materially dilute existing stockholders and that the volume of registered resale shares could pressure the trading price.
Autonomix recently effected a 1-for-21 reverse stock split, reducing outstanding common shares from 11,409,344 to 542,312 while keeping 500 million authorized shares unchanged. The independent auditor’s report on the March 31, 2026 financial statements includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Autonomix Medical, Inc. (AMIX) entered into a warrant inducement transaction with an investor holding previously issued Series D-1 and D-2 warrants. The investor agreed to immediately exercise warrants to purchase 857,462 shares of common stock at an exercise price of $5.75 per share, generating expected gross proceeds of about $4.9 million before fees and expenses.
In consideration for this cash exercise, Autonomix will issue unregistered Series E-1 and Series E-2 warrants, each to purchase up to 535,913 shares of common stock, with a $6.25 exercise price and a 5-year term. The new warrants include a 4.99% or 9.99% Beneficial Ownership Limitation, are exercisable immediately, and may be exercised on a cashless basis under specified registration shortfalls. In a fundamental transaction, holders receive alternate consideration, and the Series E-2 warrants include a Black Scholes-based redemption right.
The new warrants are being issued in a private placement under Section 4(a)(2) of the Securities Act, and Autonomix agreed to file a resale registration statement for the underlying shares within set timeframes. Maxim Group LLC acted as financial advisor and warrant inducement agent, to receive a 7.0% cash fee on proceeds plus up to $15,000 in expense reimbursement.
Autonomix Medical, Inc. is a development-stage medical device company with no revenues, focused on catheter-based neural sensing and RF ablation for pain associated with pancreatic cancer and other nerve-related disorders. For the three months ended June 30, 2026, it reported a net loss of $2.7 million, compared with $3.3 million a year earlier, as operating expenses declined 19% to $2.8 million driven mainly by lower stock-based compensation and general and administrative costs.
As of June 30, 2026, Autonomix had cash of $3.5 million, total assets of $7.6 million, working capital of $3.1 million and an accumulated deficit of $69.8 million. Net cash used in operating activities was $3.5 million for the quarter. Management estimates existing cash, together with proceeds from a July 2026 warrant exercise that raised approximately $2.6 million, will fund operations into but not beyond the first calendar quarter of 2027 and expects additional financing needs of about $25–$30 million to reach commercialization of its first indication. These conditions raise substantial doubt about its ability to continue as a going concern.
During the period, the company effected a 1-for-21 reverse stock split and subsequently regained compliance with Nasdaq’s $1.00 bid-price requirement. Capital structure is complex, with 512,394 potentially dilutive securities outstanding. Management reports ongoing material weaknesses in internal control over financial reporting, including lack of segregation of duties and technology control issues, and is adding personnel and consultants to improve controls.
Autonomix Medical, Inc. is conducting a primary at‑the‑market equity program, registering up to $1.35 million of common stock to be sold from time to time through Ladenburg Thalmann as sales agent or principal under an ATM Agreement.
The company had 971,043 shares outstanding as of July 29, 2026, with a potential increase to up to 1,266,447 shares based on an illustrative 295,404 shares sold at an assumed price of $4.57. Autonomix intends to use any net proceeds for working capital and general corporate purposes.
The filing highlights significant risks, including potential dilution, limited trading liquidity, dependence on additional financing, and exposure to Nasdaq’s new $5.0 million Market Value of Listed Securities requirement, which, if implemented and not met, could result in an immediate suspension and delisting of the stock. Audited financials also include a going‑concern explanatory paragraph.